Research ArticleDrug Discovery and Translational Medicine
Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism
James J. Vornov, Krystyna M. Wozniak, Ying Wu, Camilo Rojas, Rana Rais and Barbara S. Slusher
Journal of Pharmacology and Experimental Therapeutics September 2013, 346 (3) 406-413; DOI: https://doi.org/10.1124/jpet.113.205039
James J. Vornov
Brain Science Institute, NeuroTranslational Drug Discovery Program, Johns Hopkins University, Baltimore, Maryland (K.M.W., Y.W., C.R., R.R., B.S.S.); Department of Neurology (J.J.V., R.R., B.S.S.) and Department of Psychiatry (B.S.S.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Cerecor Inc., Baltimore, Maryland (J.J.V.)
Krystyna M. Wozniak
Brain Science Institute, NeuroTranslational Drug Discovery Program, Johns Hopkins University, Baltimore, Maryland (K.M.W., Y.W., C.R., R.R., B.S.S.); Department of Neurology (J.J.V., R.R., B.S.S.) and Department of Psychiatry (B.S.S.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Cerecor Inc., Baltimore, Maryland (J.J.V.)
Ying Wu
Brain Science Institute, NeuroTranslational Drug Discovery Program, Johns Hopkins University, Baltimore, Maryland (K.M.W., Y.W., C.R., R.R., B.S.S.); Department of Neurology (J.J.V., R.R., B.S.S.) and Department of Psychiatry (B.S.S.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Cerecor Inc., Baltimore, Maryland (J.J.V.)
Camilo Rojas
Brain Science Institute, NeuroTranslational Drug Discovery Program, Johns Hopkins University, Baltimore, Maryland (K.M.W., Y.W., C.R., R.R., B.S.S.); Department of Neurology (J.J.V., R.R., B.S.S.) and Department of Psychiatry (B.S.S.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Cerecor Inc., Baltimore, Maryland (J.J.V.)
Rana Rais
Brain Science Institute, NeuroTranslational Drug Discovery Program, Johns Hopkins University, Baltimore, Maryland (K.M.W., Y.W., C.R., R.R., B.S.S.); Department of Neurology (J.J.V., R.R., B.S.S.) and Department of Psychiatry (B.S.S.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Cerecor Inc., Baltimore, Maryland (J.J.V.)
Barbara S. Slusher
Brain Science Institute, NeuroTranslational Drug Discovery Program, Johns Hopkins University, Baltimore, Maryland (K.M.W., Y.W., C.R., R.R., B.S.S.); Department of Neurology (J.J.V., R.R., B.S.S.) and Department of Psychiatry (B.S.S.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Cerecor Inc., Baltimore, Maryland (J.J.V.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Pharmacokinetics/Pharmacodynamics of GCP II Inhibitor 2-MPPA
James J. Vornov, Krystyna M. Wozniak, Ying Wu, Camilo Rojas, Rana Rais and Barbara S. Slusher
Journal of Pharmacology and Experimental Therapeutics September 1, 2013, 346 (3) 406-413; DOI: https://doi.org/10.1124/jpet.113.205039
Research ArticleDrug Discovery and Translational Medicine
Pharmacokinetics/Pharmacodynamics of GCP II Inhibitor 2-MPPA
James J. Vornov, Krystyna M. Wozniak, Ying Wu, Camilo Rojas, Rana Rais and Barbara S. Slusher
Journal of Pharmacology and Experimental Therapeutics September 1, 2013, 346 (3) 406-413; DOI: https://doi.org/10.1124/jpet.113.205039
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement